Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2016  |  Volume : 29  |  Issue : 3  |  Page : 651-656

Brachiobasili carteriovenous fistula: a primary angioaccess for regular hemodialysis

1 Department of Vascular Surgery, Menoufia University, Menoufia, Egypt
2 Department of Vascular Surgery, Gamal Abdel Naser Hospital, Alexandria, Egypt

Correspondence Address:
Ehab Kandeel
Behira, Kafr el-dawar, 22783
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-2098.198749

Rights and Permissions

Objective The aim of  the present study was to examine the use of brachiobasilic arteriovenous fistula (BBAVF) as a primary angioaccess for regular hemodialysis in patients having metabolic syndrome in comparison with distal forearm radiocephalic arteriovenous fistula (RCAVF). Patients and methods Sixty patients recently diagnosed with end-stage renal disease fulfilling the inclusion criteria for this study were selected from a total of 638 patients referred from the nephrologists clinic to the vascular clinic at Gamal Abdel-Nasser Hospital and Shebin El-Koum Hospital. The patients were randomly divided into two groups, the RCAVF group, which included 30 patients, and the BBAVF group, which also included 30 patients. All patients suffered from metabolic syndrome. Metabolic syndrome was defined as the presence of three or more of the following: blood pressure greater than 130/90 mmHg; triglycerides greater than 150 mg/dl; high-density lipoprotein less than 50 mg/dl for women and less than 40 mg/dl for men; BMI greater than 30 kg/m 2 ; or fasting blood glucose greater than 110 mg/dl. Results The patency rate after 1 year in BBAVF group was 27 (90.0%), and nine (30.0%) in the RCAVF group. Primary access failure in the BBAVF group was 6.7%, and 3.3% in the RCAVF group. Moreover, secondary access failure in the BBAVF group was 10%, and 70% in the RCAVF group. The number of metabolic syndrome criteria and incidence of angioaccess failure showed significantly low patency of RCAVF in patients fulfilling the fourth and fifth criteria for the metabolic syndrome. Conclusion BBAVF was found to have higher patency in comparison with RCAVF in metabolic syndrome patients with end-stage renal disease. However, establishing BBAVF as the first choice in metabolic syndrome patients needs further studies in the future.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded40    
    Comments [Add]    

Recommend this journal